Formycon AG/€FYB
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Formycon AG
Formycon AG is a biotechnology company specializing in the development of biosimilar drugs, focusing on treatments in ophthalmology and immunology. ([formycon.com](https://www.formycon.com/en/company/about-us/?utm_source=openai)) Its product portfolio includes biosimilars for Lucentis® (ranibizumab) and Eylea® (aflibercept), used in treating various retinal diseases, as well as a biosimilar for Stelara® (ustekinumab), indicated for conditions like psoriasis and Crohn's disease. ([formycon.com](https://www.formycon.com/en/investor-relations/about-formycon/?utm_source=openai)) Founded in 1999 and headquartered in Planegg, Germany, Formycon operates primarily in Germany and Switzerland. ([stockanalysis.com](https://stockanalysis.com/quote/fra/FYB/company/?utm_source=openai)) The company has expanded its capabilities through strategic acquisitions, including the 2022 purchase of Bioeq GmbH, enhancing its expertise in biosimilar development and commercialization. ([biosimilardevelopment.com](https://www.biosimilardevelopment.com/doc/formycon-ag-and-athos-kg-announce-closing-of-transaction-as-well-as-bioeq-gmbh-0001?utm_source=openai)) Formycon's strategic partnerships with established pharmaceutical companies support the manufacturing and global distribution of its biosimilar products. ([formycon.com](https://www.formycon.com/en/investor-relations/about-formycon/?utm_source=openai))
Ticker
€FYB
Sector
Primary listing
XETRA
Industry
Biotechnology
Headquarters
Employees
250
ISIN
DE000A1EWVY8
Website
Formycon AG Metrics
BasicAdvanced
€486M
-
-€7.18
0.60
-
Price and volume
Market cap
€486M
Beta
0.6
52-week high
€64.40
52-week low
€19.18
Average daily volume
30K
Financial strength
Current ratio
2.804
Quick ratio
2.143
Long term debt to equity
1.97
Total debt to equity
2.294
Interest coverage (TTM)
-21.55%
Profitability
EBITDA (TTM)
114.139
Gross margin (TTM)
21.29%
Net profit margin (TTM)
-180.37%
Operating margin (TTM)
-33.68%
Effective tax rate (TTM)
12.88%
Revenue per employee (TTM)
€280,000
Management effectiveness
Return on assets (TTM)
-1.76%
Return on equity (TTM)
-26.06%
Valuation
Price to revenue (TTM)
7.055
Price to book
1.05
Price to tangible book (TTM)
27.44
Price to free cash flow (TTM)
-9.246
Free cash flow yield (TTM)
-10.82%
Free cash flow per share (TTM)
-303.92%
Growth
Revenue change (TTM)
-10.32%
Earnings per share change (TTM)
-252.22%
3-year revenue growth (CAGR)
23.92%
10-year revenue growth (CAGR)
18.66%
3-year earnings per share growth (CAGR)
81.41%
10-year earnings per share growth (CAGR)
53.38%
Bulls say / Bears say
Formycon's biosimilar FYB201 (CIMERLI®) achieved a 38% market share in the U.S. by December 2023, indicating strong market acceptance and potential for revenue growth. (ayondo.com)
The strategic investment by Gedeon Richter, acquiring a 9.1% stake in Formycon, provides significant capital infusion and opens avenues for collaborative development and commercialization. (formycon.com)
Formycon's uplisting to the Prime Standard and subsequent inclusion in the SDAX and TecDAX indices enhance its visibility and credibility among investors, potentially attracting more institutional investment. (formycon.com)
Despite increased revenues, Formycon reported a Group EBITDA of €-13.7 million for 2024, reflecting ongoing operational losses that may concern investors. (formycon.com)
The biosimilar market is highly competitive, and Formycon's products face challenges from both established pharmaceutical companies and other biosimilar developers, potentially impacting market share and pricing power. (formycon.com)
Regulatory approvals for biosimilars can be unpredictable, and any delays or rejections in Formycon's pipeline could adversely affect its financial performance and stock value. (formycon.com)
Data summarised monthly by Lightyear AI. Last updated on 29 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Formycon AG stock?
Formycon AG (FYB) has a market cap of €486M as of July 03, 2025.
What is the P/E ratio for Formycon AG stock?
The price to earnings (P/E) ratio for Formycon AG (FYB) stock is 0 as of July 03, 2025.
Does Formycon AG stock pay dividends?
No, Formycon AG (FYB) stock does not pay dividends to its shareholders as of July 03, 2025.
When is the next Formycon AG dividend payment date?
Formycon AG (FYB) stock does not pay dividends to its shareholders.
What is the beta indicator for Formycon AG?
Formycon AG (FYB) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.